351 related articles for article (PubMed ID: 17414960)
1. Effects of glucocorticoids on inflammation and arthritis.
Morand EF
Curr Opin Rheumatol; 2007 May; 19(3):302-7. PubMed ID: 17414960
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoids: action and new therapeutic insights in rheumatoid arthritis.
Kirwan J; Power L
Curr Opin Rheumatol; 2007 May; 19(3):233-7. PubMed ID: 17414948
[TBL] [Abstract][Full Text] [Related]
3. Dual-specificity phosphatase 1: a critical regulator of innate immune responses.
Abraham SM; Clark AR
Biochem Soc Trans; 2006 Dec; 34(Pt 6):1018-23. PubMed ID: 17073741
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of glucocorticoids in rheumatoid arthritis.
Spies CM; Bijlsma JW; Burmester GR; Buttgereit F
Curr Opin Pharmacol; 2010 Jun; 10(3):302-7. PubMed ID: 20202903
[TBL] [Abstract][Full Text] [Related]
5. Regulation of innate immunity by MAPK dual-specificity phosphatases: knockout models reveal new tricks of old genes.
Salojin K; Oravecz T
J Leukoc Biol; 2007 Apr; 81(4):860-9. PubMed ID: 17289800
[TBL] [Abstract][Full Text] [Related]
6. The molecular complexity of glucocorticoid actions in inflammation - a four-ring circus.
Goulding NJ
Curr Opin Pharmacol; 2004 Dec; 4(6):629-36. PubMed ID: 15525555
[TBL] [Abstract][Full Text] [Related]
7. Novel therapeutic agents targeting the glucocorticoid receptor for inflammation and cancer.
Sommer P; Ray DW
Curr Opin Investig Drugs; 2008 Oct; 9(10):1070-7. PubMed ID: 18821468
[TBL] [Abstract][Full Text] [Related]
8. Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance.
Small GW; Shi YY; Higgins LS; Orlowski RZ
Cancer Res; 2007 May; 67(9):4459-66. PubMed ID: 17483361
[TBL] [Abstract][Full Text] [Related]
9. Low-dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy.
Bijlsma JW; van der Goes MC; Hoes JN; Jacobs JW; Buttgereit F; Kirwan J
Ann N Y Acad Sci; 2010 Apr; 1193():123-6. PubMed ID: 20398017
[TBL] [Abstract][Full Text] [Related]
10. Effects of glucocorticoid treatment on focal and systemic bone loss in rheumatoid arthritis.
Di Munno O; Delle Sedie A
J Endocrinol Invest; 2008 Jul; 31(7 Suppl):43-7. PubMed ID: 18791351
[TBL] [Abstract][Full Text] [Related]
11. The antiproliferative effect of sildenafil on pulmonary artery smooth muscle cells is mediated via upregulation of mitogen-activated protein kinase phosphatase-1 and degradation of extracellular signal-regulated kinase 1/2 phosphorylation.
Li B; Yang L; Shen J; Wang C; Jiang Z
Anesth Analg; 2007 Oct; 105(4):1034-41, table of contents. PubMed ID: 17898384
[TBL] [Abstract][Full Text] [Related]
12. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index.
Schäcke H; Berger M; Rehwinkel H; Asadullah K
Mol Cell Endocrinol; 2007 Sep; 275(1-2):109-17. PubMed ID: 17630119
[TBL] [Abstract][Full Text] [Related]
13. [Glucocorticoids in rheumatoid arthritis: almost always or hardly ever?].
Blanco-Morales EA; Bravo-Ferrer Acosta JM; Rubio Romero E; Gil González E; Gantes Pedraza MÁ
Reumatol Clin; 2011; 7(6):407-11. PubMed ID: 22078702
[TBL] [Abstract][Full Text] [Related]
14. MAP kinase phosphatase 1: a novel mediator of biological effects of glucocorticoids?
Clark AR
J Endocrinol; 2003 Jul; 178(1):5-12. PubMed ID: 12844330
[TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoid use in rheumatoid arthritis: benefits, mechanisms, and risks.
Townsend HB; Saag KG
Clin Exp Rheumatol; 2004; 22(5 Suppl 35):S77-82. PubMed ID: 15552519
[TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis.
Strehl C; van der Goes MC; Bijlsma JW; Jacobs JW; Buttgereit F
Expert Opin Investig Drugs; 2017 Feb; 26(2):187-195. PubMed ID: 28043173
[TBL] [Abstract][Full Text] [Related]
18. Safety of low- to medium-dose glucocorticoid treatment in rheumatoid arthritis: myths and reality over the years.
Santiago T; da Silva JA
Ann N Y Acad Sci; 2014 May; 1318():41-9. PubMed ID: 24814757
[TBL] [Abstract][Full Text] [Related]
19. MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis.
Clark P; Rowland SE; Denis D; Mathieu MC; Stocco R; Poirier H; Burch J; Han Y; Audoly L; Therien AG; Xu D
J Pharmacol Exp Ther; 2008 May; 325(2):425-34. PubMed ID: 18287210
[TBL] [Abstract][Full Text] [Related]
20. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy.
García-Gómez C; Nolla JM; Valverde J; Narváez J; Corbella E; Pintó X
Eur J Clin Invest; 2008 Sep; 38(9):686-92. PubMed ID: 18837746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
